Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours - Wikidata - thesis-toulmin - TriplyDB

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

http://www.wikidata.org/entity/Q37182210

about

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.The lymphatic system and pancreatic cancer.An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer

P2860

Q26768483-9150F8F1-A49F-4F0B-86AA-58B6B249E563 Q28078610-E0854D2D-D2D5-498A-A806-556825E9F21B Q30364864-C0402EE0-F64F-4306-ADE5-86D8C4272D93 Q33430940-3A5C4A18-5E53-4B98-A9EE-7FA1809AE186 Q33737587-0708FB1C-437D-49CF-8804-3452E1BF7CBE Q34314062-49E7A845-D5AF-481B-9435-900F89E5694A Q36482433-A73314BF-B417-44AF-A8F3-769ABABD1D41 Q36708349-51C86CD7-51C4-4581-8CAB-C37AA653E662 Q36782339-1CD0186C-78A9-40FA-8AB8-D51D08E6C85D Q38250467-7C03A4DE-5B5B-4E91-A011-F21E8C1EBA69 Q38331666-C83E68F6-13AE-4D30-91A2-33434E346217 Q38689578-B2D5DD86-A302-4139-87A8-1A3787E91BD3 Q38835123-F76596CF-4719-4FED-B0F8-6165563ACAF0 Q40429391-FD309AD6-CEEA-45EB-BA80-89F977E0335B Q41559421-407F41D6-9DF6-4652-9BE5-231A62318C5F Q41679292-3C81B632-DD5B-499F-9E66-9FD77F87A3D4 Q47128709-34261F0D-9076-47F7-B3AB-C5839362E67A Q48295398-B97BED82-E0B6-410A-8700-76E5118C4A38 Q55064836-27AA8489-6F3C-4D9F-BCD2-D0F4B9A85457 Q58547850-F35646DE-EBC4-4CC5-B65B-FDC4B36E1D0E

P2860

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

http://www.wikidata.org/entity/Q37182210

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II study of pazopanib mo ...... creatic neuroendocrine tumours

@en

Phase II study of pazopanib mo ...... reatic neuroendocrine tumours.

@nl

type

label

Phase II study of pazopanib mo ...... creatic neuroendocrine tumours

@en

Phase II study of pazopanib mo ...... reatic neuroendocrine tumours.

@nl

prefLabel

Phase II study of pazopanib mo ...... creatic neuroendocrine tumours

@en

Phase II study of pazopanib mo ...... reatic neuroendocrine tumours.

@nl

P1433

Q37182210-6017E12A-7D88-428B-9A0B-3BFB4396570F

P1476

Q37182210-7145247E-38AD-47A9-B600-5C06DC30D04B

P2093

Q37182210-269F586E-48B4-4D36-9048-6052511D8186

Q37182210-34EE0471-78E3-4669-9D97-8FD0441982B1

Q37182210-3EC69CD0-6DDE-4FCE-878B-BD6DB2675D05

Q37182210-556E3CF8-AA95-4D80-B1EE-1287BDE1EB4D

Q37182210-5CC40DA3-9A86-400D-BDA4-1860D51E5F06

Q37182210-86A09A80-7C2B-41B3-B74F-652FF8C4D973

Q37182210-9E7EDCDD-8D41-4334-9C98-B187770C0708

Q37182210-A21620EB-E61E-4A10-979A-55562D79D30E

Q37182210-BCC6250A-CB49-4761-AE99-3F324A92EABA

Q37182210-DC9201DF-E2CD-4D1C-BF0C-31124E5DDD11

P2860

Q37182210-0954946D-261E-4B8D-9702-C87BB320FC86

Q37182210-2E0C2CED-CFA1-400A-B595-2F1640417707

Q37182210-3B7259DC-8DED-4A77-8EB7-90A635624834

Q37182210-3D0E96EF-B34D-499E-9109-2F4BB6CB9896

Q37182210-3E38D46B-7675-4796-A373-2A577CEF34FC

Q37182210-5894FFAB-9CBC-4CDA-B971-F5DB72771C16

Q37182210-61C82CBC-4F0B-4C98-813F-464A718205F9

Q37182210-76295341-072A-4118-BB77-64F304329B60

Q37182210-77F82313-B176-4267-A0FC-60EA7BE2575D

Q37182210-789BB4C7-49A2-45B7-AD9E-E13B61B52D2D

P2888

Q37182210-61C08F6C-5D08-43DE-B957-7AA53332BDA6

P304

Q37182210-E2F55B51-2938-45A3-844C-67C9BDE23B73

P31

Q37182210-53C5EA97-FD6D-4F17-ACC6-3C5C72B59D51

P356

Q37182210-E4EEE756-B479-4B21-B892-E8063794FB59

P407

Q37182210-C93214AA-5BCE-4788-AA00-373ECF88830C

P433

Q37182210-1CA1099A-AA85-4688-9AA7-1790EC17C8CA

P478

Q37182210-B7335D09-8985-446E-AFCA-250848431C95

P577

Q37182210-732E383E-1AFD-410F-93CB-FAAD4DCE8085

P5875

Q37182210-157B3126-2085-4E30-90D5-43FD164A6FA8

P698

Q37182210-BC5E2C9E-44A0-43AA-8939-A64CF39005B8

P932

Q37182210-8401FF55-AB5F-40D3-B48F-EB1EFB9B947E

P356

P1433

British Journal of Cancer

P1476

Phase II study of pazopanib mo ...... creatic neuroendocrine tumours

@en

P2093

H K Ahn

http://www.w3.org/2001/XMLSchema#string

H Kim

http://www.w3.org/2001/XMLSchema#string

H Y Lim

http://www.w3.org/2001/XMLSchema#string

J Lee

http://www.w3.org/2001/XMLSchema#string

J O Park

http://www.w3.org/2001/XMLSchema#string

J Y Choi

http://www.w3.org/2001/XMLSchema#string

K-M Kim

http://www.w3.org/2001/XMLSchema#string

S H Park

http://www.w3.org/2001/XMLSchema#string

S-H Choi

http://www.w3.org/2001/XMLSchema#string

W K Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

A 5-decade analysis of 13,715 carcinoid tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

P2888

P304

1414-1419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.470

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256290574

http://www.w3.org/2001/XMLSchema#string

P698

23989950

http://www.w3.org/2001/XMLSchema#string

P932

3776983

http://www.w3.org/2001/XMLSchema#string